AU2012299060B2 - Meta-substituted biphenyl peripherally restricted FAAH inhibitors - Google Patents

Meta-substituted biphenyl peripherally restricted FAAH inhibitors Download PDF

Info

Publication number
AU2012299060B2
AU2012299060B2 AU2012299060A AU2012299060A AU2012299060B2 AU 2012299060 B2 AU2012299060 B2 AU 2012299060B2 AU 2012299060 A AU2012299060 A AU 2012299060A AU 2012299060 A AU2012299060 A AU 2012299060A AU 2012299060 B2 AU2012299060 B2 AU 2012299060B2
Authority
AU
Australia
Prior art keywords
compound
faah
pain
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012299060A
Other languages
English (en)
Other versions
AU2012299060A1 (en
Inventor
Tiziano Bandiera
Marco Mor
Guillermo Moreno-Sanz
Daniele Piomelli
Giorgio Tarzia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Parma
Universita degli Studi di Urbino "Carlo Bo"
Fondazione Istituto Italiano di Tecnologia
University of California San Diego UCSD
Original Assignee
Degli Studi Di Parma, University of
Degli Studi Di Urbino Carlo Bo, University of
Universita degli Studi di Parma
Universita degli Studi di Urbino "Carlo Bo"
Fondazione Istituto Italiano di Tecnologia
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degli Studi Di Parma, University of, Degli Studi Di Urbino Carlo Bo, University of, Universita degli Studi di Parma, Universita degli Studi di Urbino "Carlo Bo", Fondazione Istituto Italiano di Tecnologia, University of California Berkeley, University of California San Diego UCSD filed Critical Degli Studi Di Parma, University of
Publication of AU2012299060A1 publication Critical patent/AU2012299060A1/en
Application granted granted Critical
Publication of AU2012299060B2 publication Critical patent/AU2012299060B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
AU2012299060A 2011-08-19 2012-08-17 Meta-substituted biphenyl peripherally restricted FAAH inhibitors Active AU2012299060B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525636P 2011-08-19 2011-08-19
US61/525,636 2011-08-19
PCT/US2012/051478 WO2013028570A2 (en) 2011-08-19 2012-08-17 Meta-substituted biphenyl peripherally restricted faah inhibitors

Publications (2)

Publication Number Publication Date
AU2012299060A1 AU2012299060A1 (en) 2014-04-03
AU2012299060B2 true AU2012299060B2 (en) 2017-06-01

Family

ID=47747054

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012299060A Active AU2012299060B2 (en) 2011-08-19 2012-08-17 Meta-substituted biphenyl peripherally restricted FAAH inhibitors

Country Status (12)

Country Link
US (1) US9745255B2 (enExample)
EP (1) EP2744778B1 (enExample)
JP (1) JP6092870B2 (enExample)
KR (1) KR102079404B1 (enExample)
CN (1) CN104203906B (enExample)
AU (1) AU2012299060B2 (enExample)
BR (1) BR112014003886B1 (enExample)
CA (1) CA2844812C (enExample)
DK (1) DK2744778T3 (enExample)
ES (1) ES2708723T3 (enExample)
MX (1) MX354772B (enExample)
WO (1) WO2013028570A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100485727B1 (ko) * 2004-06-24 2005-04-27 주식회사 바이오리더스 폴리감마글루탐산-비타민 복합체 및 그 용도
CN104203906B (zh) 2011-08-19 2018-03-13 加利福尼亚大学董事会 间位取代的联苯基外周限制性faah抑制剂
WO2014023325A1 (en) * 2012-08-06 2014-02-13 Fondazione Istituto Italiano Di Tecnologia Multitarget faah and cox inhibitors and therapeutical uses thereof
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
US10525012B2 (en) * 2015-08-11 2020-01-07 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
US11883381B2 (en) * 2016-05-12 2024-01-30 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
PH12018000077B1 (en) 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
PH12018000227A1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
GB201802326D0 (en) 2018-02-13 2018-03-28 Ucl Business Plc Gene therapy
WO2019173394A1 (en) 2018-03-05 2019-09-12 Wylder Nation Foundation Compositions and methods for activating signaling through the cb1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
KR20210138572A (ko) * 2019-01-10 2021-11-19 트라벡타 테라퓨틱스 피티이. 엘티디. 아난다미드 화합물
CA3186853A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
CN120965462A (zh) * 2025-10-17 2025-11-18 四川奥邦古得药业有限公司 用于生产3,5-二醚戊苯的方法及其在制备3,5-二羟基戊苯中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063714A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
US20090048337A1 (en) * 2002-10-07 2009-02-19 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
WO2012015704A2 (en) * 2010-07-28 2012-02-02 The Regents Of The University Of California Peripherally restricted faah inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325889A (en) 1978-08-04 1982-04-20 Bayer Aktiengesellschaft Process for the preparation of 1-amino-8-naphthol-3,6-disulphonic acid (H-acid)
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
DE69314148T2 (de) 1992-12-17 1998-01-15 Valeo Systemes Essuyage Stromversorgungsverfahren und -vorrichtung für einen elektrischen Motor zum Antrieb eines Scheibenwischers eines Kraftfahrzeugs
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
CA2273856A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
GB9701453D0 (en) 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
TR200002466T2 (tr) 1998-02-26 2000-12-21 Akzo Nobel N.V. Azetidin ve pirolidin türevleri
CA2330681C (en) 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US20030134894A1 (en) 1999-04-07 2003-07-17 Daniele Piomelli Methods of treating mental diseases, inflammation and pain
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
NZ537225A (en) 2002-05-16 2008-09-26 Sepracor Inc Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
FR2842808B1 (fr) 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
FR2850377B1 (fr) 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
US9316633B2 (en) 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
TW200948805A (en) 2008-03-07 2009-12-01 Sigma Tau Ind Farmaceuti Enol carbamate derivatives as modulators of fatty acid amide hydrolase
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
WO2012167133A2 (en) 2011-06-01 2012-12-06 The Regents Of The University Of California Inhibitors of anandamide transport and their therapeutic uses
CN104203906B (zh) 2011-08-19 2018-03-13 加利福尼亚大学董事会 间位取代的联苯基外周限制性faah抑制剂
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090048337A1 (en) * 2002-10-07 2009-02-19 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
WO2008063714A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
WO2012015704A2 (en) * 2010-07-28 2012-02-02 The Regents Of The University Of California Peripherally restricted faah inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FORSTER, L. et al, Bioorganic & Medicinal Chemistry, 2010, vol. 18, pp. 945-952 *
KATHURIA, S. et al, Nature Medicine, 2003, vol. 9, pp. 176-181 *

Also Published As

Publication number Publication date
WO2013028570A2 (en) 2013-02-28
US9745255B2 (en) 2017-08-29
NZ622480A (en) 2016-05-27
EP2744778A2 (en) 2014-06-25
HK1198644A1 (en) 2015-05-22
AU2012299060A1 (en) 2014-04-03
MX354772B (es) 2018-03-21
MX2014001966A (es) 2015-04-08
CA2844812A1 (en) 2013-02-28
WO2013028570A3 (en) 2013-04-18
EP2744778A4 (en) 2015-04-08
EP2744778B1 (en) 2019-01-16
ES2708723T3 (es) 2019-04-10
JP6092870B2 (ja) 2017-03-08
CN104203906A (zh) 2014-12-10
CA2844812C (en) 2019-10-22
CN104203906B (zh) 2018-03-13
JP2014527532A (ja) 2014-10-16
KR20150100485A (ko) 2015-09-02
BR112014003886B1 (pt) 2022-04-19
US20140288170A1 (en) 2014-09-25
BR112014003886A2 (pt) 2017-03-21
DK2744778T3 (en) 2019-03-04
KR102079404B1 (ko) 2020-02-19
BR112014003886A8 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
AU2012299060B2 (en) Meta-substituted biphenyl peripherally restricted FAAH inhibitors
CA2843265C (en) Peripherally restricted faah inhibitors
Piomelli et al. N-acylethanolamine acid amidase (NAAA): structure, function, and inhibition
Höglinger et al. Intracellular sphingosine releases calcium from lysosomes
CN100408556C (zh) 通过阻断花生四烯酰乙醇酰胺的水解调节焦虑
US10384997B2 (en) Bio-stable cannabinoid compounds and methods for enhancing their physiological concentration
US20170283837A1 (en) BIOENZYMATIC SYNTHESIS OF THC-v, CBV AND CBN AND THEIR USE AS THERAPEUTIC AGENTS
US20080045513A1 (en) Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
HK1198644B (en) Meta-substituted biphenyl peripherally restricted faah inhibitors
US10414721B1 (en) Inhibitor of endocannabinoid cellular reuptake
Elumalai et al. Development of potent cholinesterase inhibitors based on a marine pharmacophore
NZ622480B2 (en) Meta-substituted biphenyl peripherally restricted faah inhibitors
US10537545B2 (en) Ceramide derivatives as anticancer agents
US20220117965A1 (en) Method of inhibiting trem-1
US20230225991A1 (en) Compounds for use in the treatment of acute intermittent porphyria
Seixas Xavier et al. Synthesis and In Vitro Anti Leishmania amazonensis Biological Screening of Morita-Baylis-Hillman Adducts Prepared from Eugenol, Thymol and Carvacrol.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)